ADA Scientific Sessions - American Diabetes Association Scientific Sessions

Pharmacists can play a crucial role in diabetes management by implementing standing order protocols for medication titration and serving as a bridge between patients and other health care providers.

Many patients who took technosphere insulin saw improvements in hemoglobin A1c, but other patients saw worsening with the drug.

The CATALYST trial has identified hypercortisolism as a significant factor in approximately 1.2 to 1.3 million poorly controlled diabetes patients in the United States.

Approximately 81% of individual said Tandem Mobi reduced the burden of managing diabetes and 87% said it helped manage diabetes effectively.

American Diabetes Association Scientific Sessions speaker Ivan de Araujo discusses how regulation of blood glucose levels and the influence of food preferences can be significant for diabetes care.

Benefits of semaglutide on cardiovascular outcomes, such as death, non-fatal myocardial infarction, and non-fatal stoke, were also presented at the session at American Diabetes Association 84th Scientific Sessions.

Teplizumab (Tzield; Sanofi) has the potential to delay type 1 diabetes and the onset of stage 3 diabetes, but must be started in stage 1 of the disease.

Food is medicine is a framework of policy and behavioral interventions, improving population health through access to healthy foods to increase food and nutrition security.

W. Timothy Garvey expressed concern over limited access to effective obesity medications like Ozempic due to shortages and high costs, urging stakeholders to work together on developing solutions.

Semaglutide significantly improved heart failure symptoms and quality of life through weight loss and direct effects on heart tissue.

Potential concerns surrounding GLP-include pancreatitis, pancreatic cancer, colorectal cancer, suicide and other phycological effects, and thyroid cancer.

Jennifer Goldman discusses the importance of collaborative care between providers like endocrinologists, cardiologists, primary care physicians, and pharmacists to manage diabetes and prevent cardiovascular events.

There are approximately 98 million individuals have prediabetes, but approximately only 15 million actually know they have prediabetes.

Semaglutide was found to have effects on glycemia, inflammation, and heart failure outcomes in sub analyses.

Based on these results, tirzepatide could be first medication approved for treatment of obstructive sleep apnea in patients with obesity.

Managing these treatments involves many considerations, including glycemic control and nutrition, among others.

Presenters at the American Diabetes Association 84th Scientific Sessions analyzed potential developments in treatment for patients with diabetes and diabetic kidney disease.

The study shows that tirzepatide significantly improves secondary outcomes in patients with sleep apnea.

With improved technology and innovations for diabetes, it is essential for health care providers and health agencies to collaborate to combat rising rates of diabetes.

American Diabetes Association Scientific Sessions speaker Ivan de Araujo emphasizes the importance of the pharmacist’s role in diabetes care and his hopes for the future of care.

Pharmacy Times will be at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida from June 21 to June 24, 2024.

In a study of individuals with Medicare, the incidence of type 2 diabetes was associated with approximately $30,000 to $98,000 excess lifetime medical expenditures.

All individuals with type 1 diabetes on the therapy had restored insulin secretion, improved glycemic control, improved time-in-range reduction, or elimination of exogenous insulin usage.

The prevalence of undiagnosed diabetes in earlier years in racial and ethnic minorities and lower education groups, leading to a decline in incidence over time.

The collaboration will focus on engaging with health experts and opinion leaders to examine data to gain a better understanding of the role continuous glucose monitoring systems have in personalized therapeutic nutrition.

The results of the study were presented at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, California and were also published in The Lancet.

The American Diabetes Association showcased advancements in diabetes technology revolving around improving glucose control devices and treating diabetic retinopathy at the 83rd Scientific Sessions.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed what changes would be necessary to continue providing quality virtual health care to patients with diabetes.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed the challenges encountered by health systems and patients during the shift to online care.

Similar effects were seen both with and without an SGLT2 inhibitor, according to investigators.